JP2016521256A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016521256A5 JP2016521256A5 JP2016503215A JP2016503215A JP2016521256A5 JP 2016521256 A5 JP2016521256 A5 JP 2016521256A5 JP 2016503215 A JP2016503215 A JP 2016503215A JP 2016503215 A JP2016503215 A JP 2016503215A JP 2016521256 A5 JP2016521256 A5 JP 2016521256A5
- Authority
- JP
- Japan
- Prior art keywords
- asparagine
- alkyl
- aryl
- heterocyclyl
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- SCWQOYNSFXYAEZ-OQSGQEIMSA-N CC(C)[C@@H](C(N[C@@H](CCCNC(N)=O)C(Nc1ccc(CNC(SCCC(N(C)[C@@H](C)C(O[C@@H](CC(N(C)c2c(C)c(OC)cc(C/C(/C)=C/C=C/[C@H]([C@@](C3)(N4)O)OC)c2)=O)[C@]2(C)O[C@H]2[C@H](C)[C@H]3OC4=O)=O)=O)=S)cc1)=O)=O)NC(CCCCCN(C(C=C1)=O)C1=O)=O Chemical compound CC(C)[C@@H](C(N[C@@H](CCCNC(N)=O)C(Nc1ccc(CNC(SCCC(N(C)[C@@H](C)C(O[C@@H](CC(N(C)c2c(C)c(OC)cc(C/C(/C)=C/C=C/[C@H]([C@@](C3)(N4)O)OC)c2)=O)[C@]2(C)O[C@H]2[C@H](C)[C@H]3OC4=O)=O)=O)=S)cc1)=O)=O)NC(CCCCCN(C(C=C1)=O)C1=O)=O SCWQOYNSFXYAEZ-OQSGQEIMSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361792216P | 2013-03-15 | 2013-03-15 | |
| US61/792,216 | 2013-03-15 | ||
| PCT/US2014/029757 WO2014145090A1 (en) | 2013-03-15 | 2014-03-14 | Biologically active molecules, conjugates thereof, and therapeutic uses |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019059070A Division JP2019135239A (ja) | 2013-03-15 | 2019-03-26 | 生物活性分子、そのコンジュゲート、及び治療用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016521256A JP2016521256A (ja) | 2016-07-21 |
| JP2016521256A5 true JP2016521256A5 (enExample) | 2017-04-20 |
| JP6847388B2 JP6847388B2 (ja) | 2021-03-31 |
Family
ID=50933481
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016503215A Active JP6847388B2 (ja) | 2013-03-15 | 2014-03-14 | 生物活性分子、そのコンジュゲート、及び治療用途 |
| JP2019059070A Pending JP2019135239A (ja) | 2013-03-15 | 2019-03-26 | 生物活性分子、そのコンジュゲート、及び治療用途 |
| JP2021043270A Pending JP2021105007A (ja) | 2013-03-15 | 2021-03-17 | 生物活性分子、そのコンジュゲート、及び治療用途 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019059070A Pending JP2019135239A (ja) | 2013-03-15 | 2019-03-26 | 生物活性分子、そのコンジュゲート、及び治療用途 |
| JP2021043270A Pending JP2021105007A (ja) | 2013-03-15 | 2021-03-17 | 生物活性分子、そのコンジュゲート、及び治療用途 |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US10570151B2 (enExample) |
| EP (2) | EP3964237B1 (enExample) |
| JP (3) | JP6847388B2 (enExample) |
| KR (1) | KR102306490B1 (enExample) |
| CN (1) | CN105188766B (enExample) |
| AU (1) | AU2014233385C1 (enExample) |
| BR (1) | BR112015022585B1 (enExample) |
| CA (1) | CA2902872A1 (enExample) |
| CL (1) | CL2015002765A1 (enExample) |
| EA (1) | EA038512B1 (enExample) |
| ES (1) | ES2996807T3 (enExample) |
| IL (1) | IL240418B (enExample) |
| MA (1) | MA38496B2 (enExample) |
| MX (1) | MX379256B (enExample) |
| MY (1) | MY183572A (enExample) |
| PH (1) | PH12015502131B1 (enExample) |
| SG (1) | SG11201507481WA (enExample) |
| WO (1) | WO2014145090A1 (enExample) |
| ZA (1) | ZA201505813B (enExample) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8542802B2 (en) | 2007-02-15 | 2013-09-24 | Global Tel*Link Corporation | System and method for three-way call detection |
| KR20210132742A (ko) | 2012-12-21 | 2021-11-04 | 알트루바이오 인코퍼레이티드 | 친수성 자기-희생 링커 및 그것의 포합체 |
| EP3964237B1 (en) | 2013-03-15 | 2026-02-18 | Regeneron Pharmaceuticals, Inc. | Biologically active molecules, conjugates thereof, and therapeutic uses |
| TWI641620B (zh) | 2013-08-21 | 2018-11-21 | 再生元醫藥公司 | 抗－ｐｒｌｒ抗體及其用途 |
| US9545451B2 (en) | 2013-08-21 | 2017-01-17 | Regeneron Pharmaceuticals, Inc. | Anti-PRLR antibodies and methods for killing PRLR-expressing cells |
| AU2014311361B2 (en) | 2013-08-26 | 2018-11-29 | Regeneron Pharmaceuticals, Inc. | Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses |
| AU2015229591B2 (en) | 2014-03-11 | 2020-10-22 | Regeneron Pharmaceuticals, Inc. | Anti-EGFRvlll antibodies and uses thereof |
| WO2015187596A2 (en) | 2014-06-02 | 2015-12-10 | Regeneron Pharmaceuticals, Inc. | Biologically active molecule conjugates, reagents and methods of manufacture, and therapeutic uses |
| KR20170020868A (ko) | 2014-06-20 | 2017-02-24 | 바이오얼라이언스 씨.브이. | 항-폴레이트 수용체 알파 (fra) 항체-약물 컨쥬게이트 및 그것의 사용 방법 |
| CA2978340C (en) * | 2015-03-27 | 2024-05-28 | Regeneron Pharmaceuticals, Inc. | Maytansinoid derivatives, conjugates thereof, and methods of use |
| EP3308801A4 (en) | 2015-06-09 | 2019-02-27 | XDCExplorer (Shanghai) Co., Ltd. | ANTIBODY-ACTIVE CONJUGATE, INTERMEDIATE PRODUCT, METHOD OF MANUFACTURE, PHARMACEUTICAL COMPOSITION AND USE THEREOF |
| JP6993958B2 (ja) | 2015-07-06 | 2022-02-04 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 多重特異性抗原結合分子およびその使用 |
| WO2017120534A1 (en) | 2016-01-08 | 2017-07-13 | Bioalliance C.V. | Tetravalent anti-psgl-1 antibodies and uses thereof |
| MX390630B (es) | 2016-01-25 | 2025-03-21 | Regeneron Pharma | Derivados de maitansinoide, conjugados de los mismos y metodos de uso. |
| KR102775461B1 (ko) | 2016-04-01 | 2025-02-28 | 어비디티 바이오사이언시스 인크. | 핵산-폴리펩타이드 조성물 및 이의 용도 |
| WO2017190079A1 (en) | 2016-04-28 | 2017-11-02 | Regeneron Pharmaceuticals, Inc. | Methods of making multispecific antigen-binding molecules |
| SI3464336T1 (sl) | 2016-06-01 | 2022-06-30 | Athira Pharma, Inc. | Spojine |
| KR102531251B1 (ko) | 2016-09-23 | 2023-05-15 | 리제너론 파아마슈티컬스, 인크. | 이특이적 항-muc16-cd3 항체 및 항-muc16 약물 접합체 |
| KR102520731B1 (ko) | 2016-09-23 | 2023-04-14 | 리제너론 파아마슈티컬스, 인크. | 항-steap2 항체, 항체-약물 컨쥬게이트, 및 steap2 및 cd3에 결합하는 이중특이적 항원-결합 분자, 및 이의 용도 |
| TWI782930B (zh) * | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法 |
| MX2019006131A (es) | 2016-11-29 | 2019-08-21 | Regeneron Pharma | Metodos para tratar cancer de mama positivo para prlr. |
| KR20240172236A (ko) | 2017-01-06 | 2024-12-09 | 어비디티 바이오사이언시스 인크. | 핵산-폴리펩티드 조성물 및 엑손 스키핑을 유도하는 방법 |
| US12667557B2 (en) | 2017-02-28 | 2026-06-30 | Daiichi Sankyo Company, Limited | Method for treating EGFR-TKI-resistant non-small cell lung cancer by administration of anti-HER3 antibody-drug conjugate |
| TW201836647A (zh) | 2017-04-06 | 2018-10-16 | 美商艾伯維有限公司 | 抗－ｐｒｌｒ抗體藥物軛合物（ａｄｃ）及其用途 |
| KR20250008984A (ko) | 2017-05-18 | 2025-01-16 | 리제너론 파마슈티칼스 인코포레이티드 | 사이클로덱스트린 단백질 약물 접합체 |
| AU2018281280B2 (en) | 2017-06-07 | 2024-12-19 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for internalizing enzymes |
| TWI804499B (zh) | 2017-06-23 | 2023-06-11 | 美商維洛斯生物公司 | Ror1抗體免疫接合物 |
| GB201711809D0 (en) | 2017-07-21 | 2017-09-06 | Governors Of The Univ Of Alberta | Antisense oligonucleotide |
| SG11202002517RA (en) | 2017-09-22 | 2020-04-29 | Avidity Biosciences Inc | Nucleic acid-polypeptide compositions and methods of inducing exon skipping |
| SG11202003126VA (en) | 2017-10-04 | 2020-05-28 | Avidity Biosciences Inc | Nucleic acid-polypeptide compositions and uses thereof |
| CA3247730A1 (en) | 2017-11-07 | 2025-10-30 | Regeneron Pharmaceuticals, Inc. | Hydrophilic linkers for antibody drug conjugates |
| CN118638787A (zh) | 2017-12-06 | 2024-09-13 | 艾维迪提生物科学公司 | 治疗肌萎缩和强直性肌营养不良的组合物和方法 |
| JP7328990B2 (ja) | 2018-04-30 | 2023-08-17 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｈｅｒ２及び／またはａｐｌｐ２に結合する抗体及び二重特異性抗原結合分子、ならびにそれらのコンジュゲート及び使用 |
| EP3793591A1 (en) | 2018-05-17 | 2021-03-24 | Regeneron Pharmaceuticals, Inc. | Anti-cd63 antibodies, conjugates, and uses thereof |
| MX2020013466A (es) * | 2018-06-26 | 2021-04-19 | Immunogen Inc | Inmunoconjugados dirigidos a adam9 y métodos para usarlos. |
| WO2020059772A1 (ja) | 2018-09-20 | 2020-03-26 | 第一三共株式会社 | 抗ｈｅｒ３抗体－薬物コンジュゲート投与によるｈｅｒ３変異がんの治療 |
| IL312067B2 (en) | 2018-12-21 | 2025-08-01 | Avidity Biosciences Inc | Anti-transferrin receptor antibodies and uses thereof |
| MX2021008230A (es) * | 2019-01-07 | 2021-08-11 | Astellas Pharma Inc | Conjugado que comprende ligando y fragmento fab de anticuerpo ceacam5. |
| KR20210130755A (ko) | 2019-02-21 | 2021-11-01 | 리제너론 파마슈티칼스 인코포레이티드 | 항-met 항체 및 met에 결합하는 이중특이적 항원 결합 분자를 사용하여 안구암을 치료하는 방법 |
| WO2020219820A1 (en) | 2019-04-25 | 2020-10-29 | Avidity Biosciences, Inc. | Nucleic acid compositions and methods of multi-exon skipping |
| JP7581252B2 (ja) | 2019-06-06 | 2024-11-12 | アビディティー バイオサイエンシーズ，インク． | Ｕｎａアミダイトおよびその使用 |
| WO2020247782A1 (en) | 2019-06-06 | 2020-12-10 | Avidity Biosciences, Inc. | Nucleic acid-polypeptide compositions and uses thereof |
| CN114340684B (zh) | 2019-09-16 | 2025-09-12 | 瑞泽恩制药公司 | 用于免疫pet成像的放射性标记的met结合蛋白 |
| US11814428B2 (en) | 2019-09-19 | 2023-11-14 | Regeneron Pharmaceuticals, Inc. | Anti-PTCRA antibody-drug conjugates and uses thereof |
| CA3159770A1 (en) | 2019-11-15 | 2021-05-20 | Seagen Inc. | Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate |
| MX2022008901A (es) | 2020-01-24 | 2022-08-16 | Regeneron Pharma | Conjugados de proteinas-compuestos antivirales. |
| CA3166619A1 (en) | 2020-02-28 | 2021-09-02 | Julian Andreev | Bispecific antigen binding molecules that bind her2, and methods of use thereof |
| TW202144572A (zh) | 2020-03-19 | 2021-12-01 | 美商亞維代堤生物科學公司 | 治療臉肩胛肱骨肌肉失養症之組合物及方法 |
| KR102927945B1 (ko) | 2020-03-27 | 2026-02-23 | 어비디티 바이오사이언시스 인크. | 근이영양증의 치료용 조성물 및 방법 |
| MX2022012821A (es) | 2020-04-16 | 2022-11-07 | Regeneron Pharma | Metodos de conjugacion de diels-alder. |
| BR112023000711A2 (pt) | 2020-07-17 | 2023-01-31 | Daiichi Sankyo Co Ltd | Método para produzir uma composição de conjugado de anticorpo-fármaco, e, composição de conjugado de anticorpo-fármaco |
| US11866502B2 (en) | 2020-10-22 | 2024-01-09 | Regeneron Pharmaceuticals, Inc. | Anti-FGFR2 antibodies and methods of use thereof |
| MX2023004935A (es) | 2020-11-10 | 2023-07-07 | Regeneron Pharma | Conjugados de anticuerpos y selenio. |
| JP2024510435A (ja) | 2021-03-18 | 2024-03-07 | シージェン インコーポレイテッド | 生体活性化合物の内部移行複合体からの選択的薬物放出 |
| JP7624255B2 (ja) | 2021-03-31 | 2025-01-30 | 日本マイクロバイオファーマ株式会社 | 抗体薬物複合体の製造方法及びそれに用いる酵素 |
| IL307498A (en) | 2021-04-05 | 2023-12-01 | Altheia Science S R L | Diagnosis and treatment of myeloid disorders and acute leukemia using antigens specific to new tumors |
| JP2024527235A (ja) * | 2021-06-22 | 2024-07-24 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ＥＧＦＲｖＩＩＩ抗体薬物コンジュゲート及びその使用 |
| EP4401792A4 (en) | 2021-09-16 | 2025-12-03 | Avidity Biosciences Inc | COMPOSITIONS AND METHODS OF TREATMENT OF FACIO-SCAPULO-HUMERAL MUSCULAR DYSTROPHY |
| KR20240125036A (ko) | 2021-12-23 | 2024-08-19 | 마이레큘, 인크. | 폴리뉴클레오타이드의 전달을 위한 조성물 |
| US12071621B2 (en) | 2022-04-05 | 2024-08-27 | Avidity Biosciences, Inc. | Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping |
| WO2023194501A1 (en) | 2022-04-05 | 2023-10-12 | Altheia Science S.R.L. | Treatment of myeloid disorders and acute leukemias targeting novel tumor specific antigens |
| KR20230144961A (ko) | 2022-04-07 | 2023-10-17 | 트윈피그바이오랩(주) | Itgb2 매개 약물전달체 |
| CN120659627A (zh) | 2022-07-29 | 2025-09-16 | 瑞泽恩制药公司 | 用于转铁蛋白受体（tfr）介导的脑和肌肉递送的组合物和方法 |
| AU2023379457A1 (en) | 2022-11-14 | 2025-05-15 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes |
| JPWO2024248123A1 (enExample) | 2023-06-02 | 2024-12-05 | ||
| US12491257B2 (en) | 2023-06-27 | 2025-12-09 | Avidity Biosciences, Inc. | Compositions and methods of using PRKAG2-targeting antibody-oligonucleotide conjugates |
| AU2024308906A1 (en) | 2023-06-30 | 2026-02-05 | Atrium Therapeutics, Inc. | Compositions and methods of using pln-targeting antibody-oligonucleotide conjugates |
| WO2025076006A2 (en) | 2023-10-02 | 2025-04-10 | Avidity Biosciences, Inc. | Antibody-oligonucleotide conjugate compositions and methods of inducing dmd exon 45 skipping |
Family Cites Families (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
| JPS5566585A (en) | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20070258987A1 (en) | 2000-11-28 | 2007-11-08 | Seattle Genetics, Inc. | Recombinant Anti-Cd30 Antibodies and Uses Thereof |
| EP1258255A1 (en) | 2001-05-18 | 2002-11-20 | Boehringer Ingelheim International GmbH | Conjugates of an antibody to CD44 and a maytansinoid |
| US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| US7771727B2 (en) * | 2002-03-01 | 2010-08-10 | The Administrators Of The Tulane Educational Fund | Conjugates of therapeutic or cytotoxic agents and biologically active peptides |
| US20090068178A1 (en) | 2002-05-08 | 2009-03-12 | Genentech, Inc. | Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin |
| US20110250133A1 (en) | 2003-01-13 | 2011-10-13 | Bracco Imaging S.P.A. | Gastrin releasing peptide compounds |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
| MXPA05014155A (es) | 2003-06-27 | 2006-05-25 | Abgenix Inc | Anticuerpos dirigidos a los mutantes de delecion de receptor de factor de crecimiento epidermico y sus usos. |
| GB0316294D0 (en) | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
| TW200539855A (en) | 2004-03-15 | 2005-12-16 | Wyeth Corp | Calicheamicin conjugates |
| BRPI0510909A2 (pt) | 2004-05-19 | 2008-12-16 | Medarex Inc | composto de ligaÇço fÁrmaco-ligante citotàxico, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula e mÉtodo para retardar ou interromper o crescimento de tumor |
| NZ551180A (en) | 2004-06-01 | 2009-10-30 | Genentech Inc | Antibody drug conjugates and methods |
| US20080305044A1 (en) | 2004-11-29 | 2008-12-11 | Seattle Genetics, Inc. | Engineered Antibodies and Immunoconjugates |
| KR101281501B1 (ko) | 2004-12-09 | 2013-07-15 | 얀센 바이오테크 인코포레이티드 | 항인테그린 면역 컨쥬게이트, 방법 및 용도 |
| US7811572B2 (en) | 2005-08-24 | 2010-10-12 | Immunogen, Inc. | Process for preparing purified drug conjugates |
| US7989595B2 (en) * | 2005-06-20 | 2011-08-02 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| AU2006262231B2 (en) | 2005-06-20 | 2013-01-24 | Psma Development Company, Llc | PSMA antibody-drug conjugates |
| ATE535529T1 (de) | 2005-08-09 | 2011-12-15 | Millennium Pharm Inc | Verfahren zur acylierung von maytansinol mit chiralen aminosäuren |
| US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
| PT2845866T (pt) | 2006-10-27 | 2017-08-09 | Genentech Inc | Anticorpos e imunoconjugados e utilizações dos mesmos |
| JP5394246B2 (ja) * | 2007-03-30 | 2014-01-22 | ジェネンテック， インコーポレイテッド | 抗体及びイムノコンジュゲートとこれらの使用方法 |
| WO2008122039A2 (en) | 2007-04-02 | 2008-10-09 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Selenocysteine mediated hybrid antibody molecules |
| PE20090245A1 (es) | 2007-05-08 | 2009-03-17 | Genentech Inc | Anticuerpos anti-muc16 disenados con cisteina y conjugados de anticuerpos y farmacos |
| US7985557B2 (en) | 2007-05-23 | 2011-07-26 | Ventana Medical Systems, Inc. | Polymeric carriers for immunohistochemistry and in situ hybridization |
| NZ587706A (en) | 2008-03-18 | 2012-12-21 | Genentech Inc | Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use |
| ES2588194T3 (es) * | 2008-04-11 | 2016-10-31 | Seattle Genetics, Inc. | Detección y tratamiento de cáncer pancreático, de ovario y otros cánceres |
| UA108598C2 (xx) * | 2008-04-30 | 2015-05-25 | Високоефективні кон'югати та гідрофільні зшиваючі агенти (лінкери) | |
| NZ588884A (en) | 2008-04-30 | 2013-05-31 | Immunogen Inc | Cross-linkers and their uses |
| ES2560807T3 (es) | 2008-07-21 | 2016-02-22 | Polytherics Limited | Nuevos reactivos y procedimiento de conjugación de moléculas biológicas |
| US9005598B2 (en) | 2009-03-04 | 2015-04-14 | Polytherics Limited | Conjugated proteins and peptides |
| MA33256B1 (fr) * | 2009-04-01 | 2012-05-02 | Genentech Inc | Anticorps et immunoconjugués anti-fcrh5 et procédés d'utilisation |
| DK2889624T3 (en) | 2009-08-10 | 2018-12-10 | Ucl Business Plc | Reversible covalent bonding of functional molecules |
| UY32913A (es) | 2009-10-02 | 2011-04-29 | Sanofi Aventis | Nuevos maitansinoides y el uso de dichos maitansinoides para preparar conjugados con un anticuero |
| UY32914A (es) | 2009-10-02 | 2011-04-29 | Sanofi Aventis | Anticuerpos que se usan específicamente al receptor epha2 |
| CN102596922A (zh) | 2009-10-06 | 2012-07-18 | 免疫基因公司 | 有效的缀合物和亲水性连接体 |
| MY173390A (en) * | 2009-10-23 | 2020-01-22 | Takeda Pharmaceuticals Co | Anti-gcc antibody molecules and related compositions and methods |
| US8501692B2 (en) | 2009-12-14 | 2013-08-06 | The Regents Of The University Of Michigan | Compositions and methods for altering cocaine esterase activity |
| PT2528625E (pt) | 2010-04-15 | 2013-10-17 | Spirogen Sarl | Pirrolobenzodiazepinas e conjugados das mesmas |
| US20130244905A1 (en) | 2010-07-06 | 2013-09-19 | Ed Grabczyk | Reporter for RNA Polymerase II Termination |
| EP2601298B1 (en) | 2010-08-02 | 2016-11-30 | Regeneron Pharmaceuticals, Inc. | Mice that make binding proteins comprising vl domains |
| EP2611785B1 (de) | 2010-09-01 | 2014-06-04 | Bayer Intellectual Property GmbH | N-(tetrazol-5-yl)- und n-(triazol-5-yl)arylcarbonsäureamide und ihre verwendung als herbizide |
| JP5828902B2 (ja) | 2010-10-29 | 2015-12-09 | イミュノジェン， インコーポレイテッド | 非拮抗性ｅｇｆｒ結合分子およびその免疫複合体 |
| US9090629B2 (en) | 2010-11-03 | 2015-07-28 | Immunogen, Inc. | Cytotoxic agents comprising new ansamitocin derivatives |
| EP2640727B1 (en) * | 2010-11-17 | 2015-05-13 | Genentech, Inc. | Alaninyl maytansinol antibody conjugates |
| EP2709666B1 (en) | 2011-05-16 | 2021-07-14 | Koninklijke Philips N.V. | Bio-orthogonal drug activation |
| DK2714685T3 (en) | 2011-05-27 | 2017-01-09 | Ambrx Inc | FORMATIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID BOUND dolastatin |
| US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| WO2012177837A2 (en) * | 2011-06-21 | 2012-12-27 | Immunogen, Inc. | Novel maytansinoid derivatives with peptide linker and conjugates thereof |
| AU2012322934B2 (en) | 2011-10-14 | 2016-09-08 | Medimmune Limited | Pyrrolobenzodiazepines |
| JP6166728B2 (ja) | 2011-10-14 | 2017-07-19 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | ピロロベンゾジアゼピンの製造に有用な合成方法及び中間体 |
| CA2850373C (en) | 2011-10-14 | 2019-07-16 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| CA2850375C (en) | 2011-10-14 | 2019-07-02 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| WO2013068874A1 (en) | 2011-11-11 | 2013-05-16 | Pfizer Inc. | Antibody-drug conjugates |
| AU2012340174A1 (en) | 2011-11-16 | 2014-05-29 | Amgen Inc. | Methods of treating epidermal growth factor deletion mutant VIII related disorders |
| BR112014013526A8 (pt) | 2011-12-05 | 2017-06-13 | Igenica Biotherapeutics Inc | conjugados de anticorpo-fármaco e compostos, composições e métodos relacionados |
| GB201210770D0 (en) | 2012-06-18 | 2012-08-01 | Polytherics Ltd | Novel conjugation reagents |
| BR112014031613A2 (pt) | 2012-06-19 | 2017-07-25 | Polytherics Ltd | processo para preparação de conjugados de anticorpos e conjugados de anticorpos |
| HRP20180268T4 (hr) | 2012-10-23 | 2026-03-27 | Synaffix B.V. | Modificirano antitijelo, konjugat antitijela i postupak za njihovu pripremu |
| NO2789793T3 (enExample) | 2012-10-24 | 2018-01-27 | ||
| US10131682B2 (en) | 2012-11-24 | 2018-11-20 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules |
| TW201425336A (zh) | 2012-12-07 | 2014-07-01 | Amgen Inc | Ｂｃｍａ抗原結合蛋白質 |
| CN103254213B (zh) | 2012-12-21 | 2015-02-25 | 百奥泰生物科技(广州)有限公司 | 类美登素酯的制备方法及用于所述方法的组合物 |
| CN104688740A (zh) | 2012-12-21 | 2015-06-10 | 百奥泰生物科技(广州)有限公司 | 类美登素衍生物及其制备方法和用途 |
| EP3964237B1 (en) | 2013-03-15 | 2026-02-18 | Regeneron Pharmaceuticals, Inc. | Biologically active molecules, conjugates thereof, and therapeutic uses |
| CN103254311B (zh) | 2013-05-09 | 2015-05-13 | 齐鲁制药有限公司 | 一种制备抗体-美登素类生物碱药物偶联物的方法 |
| WO2014194030A2 (en) | 2013-05-31 | 2014-12-04 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
| US11229711B2 (en) | 2013-06-06 | 2022-01-25 | Magenta Therapeutics, Inc. | Linkers for antibody-drug conjugates and related compounds, compositions, and methods of use |
| US20140363454A1 (en) | 2013-06-06 | 2014-12-11 | Igenica Biotherapeutics, Inc. | Antibody-Drug Conjugates, Compositions and Methods of Use |
| WO2014197866A1 (en) | 2013-06-06 | 2014-12-11 | Igenica Biotherapeutics, Inc. | Modified antibodies and related compounds, compositions, and methods of use |
| EP3003390B1 (en) | 2013-06-06 | 2021-07-07 | Pierre Fabre Médicament | Anti-c10orf54 antibodies and uses thereof |
| US9545451B2 (en) | 2013-08-21 | 2017-01-17 | Regeneron Pharmaceuticals, Inc. | Anti-PRLR antibodies and methods for killing PRLR-expressing cells |
| AU2014311361B2 (en) | 2013-08-26 | 2018-11-29 | Regeneron Pharmaceuticals, Inc. | Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses |
| US20160354105A1 (en) | 2013-11-26 | 2016-12-08 | Segway Orthopaedics, Inc. | Surgical Blade with Viewing Aperture |
| CN115504924A (zh) | 2013-11-27 | 2022-12-23 | 雷德伍德生物科技股份有限公司 | 肼基-吡咯并化合物及用于生成缀合物的方法 |
| CN105793268B (zh) | 2013-12-02 | 2019-03-15 | 香港浸会大学 | 具有两个稠合大环的抗癌性美登木素类化合物 |
| WO2015187596A2 (en) | 2014-06-02 | 2015-12-10 | Regeneron Pharmaceuticals, Inc. | Biologically active molecule conjugates, reagents and methods of manufacture, and therapeutic uses |
| CA2978340C (en) | 2015-03-27 | 2024-05-28 | Regeneron Pharmaceuticals, Inc. | Maytansinoid derivatives, conjugates thereof, and methods of use |
| MX390630B (es) | 2016-01-25 | 2025-03-21 | Regeneron Pharma | Derivados de maitansinoide, conjugados de los mismos y metodos de uso. |
| KR102520731B1 (ko) | 2016-09-23 | 2023-04-14 | 리제너론 파아마슈티컬스, 인크. | 항-steap2 항체, 항체-약물 컨쥬게이트, 및 steap2 및 cd3에 결합하는 이중특이적 항원-결합 분자, 및 이의 용도 |
| US11814428B2 (en) | 2019-09-19 | 2023-11-14 | Regeneron Pharmaceuticals, Inc. | Anti-PTCRA antibody-drug conjugates and uses thereof |
-
2014
- 2014-03-14 EP EP21194635.5A patent/EP3964237B1/en active Active
- 2014-03-14 WO PCT/US2014/029757 patent/WO2014145090A1/en not_active Ceased
- 2014-03-14 MX MX2015011348A patent/MX379256B/es unknown
- 2014-03-14 KR KR1020157028418A patent/KR102306490B1/ko active Active
- 2014-03-14 MY MYPI2015002247A patent/MY183572A/en unknown
- 2014-03-14 MA MA38496A patent/MA38496B2/fr unknown
- 2014-03-14 EP EP14729755.0A patent/EP2968593B1/en active Active
- 2014-03-14 BR BR112015022585-3A patent/BR112015022585B1/pt active IP Right Grant
- 2014-03-14 US US14/776,668 patent/US10570151B2/en active Active
- 2014-03-14 EA EA201500905A patent/EA038512B1/ru unknown
- 2014-03-14 SG SG11201507481WA patent/SG11201507481WA/en unknown
- 2014-03-14 CN CN201480025356.9A patent/CN105188766B/zh active Active
- 2014-03-14 JP JP2016503215A patent/JP6847388B2/ja active Active
- 2014-03-14 ES ES14729755T patent/ES2996807T3/es active Active
- 2014-03-14 CA CA2902872A patent/CA2902872A1/en active Pending
- 2014-03-14 AU AU2014233385A patent/AU2014233385C1/en active Active
-
2015
- 2015-08-06 IL IL240418A patent/IL240418B/en active IP Right Grant
- 2015-08-13 ZA ZA2015/05813A patent/ZA201505813B/en unknown
- 2015-09-15 PH PH12015502131A patent/PH12015502131B1/en unknown
- 2015-09-15 CL CL2015002765A patent/CL2015002765A1/es unknown
-
2019
- 2019-03-26 JP JP2019059070A patent/JP2019135239A/ja active Pending
-
2020
- 2020-01-10 US US16/740,312 patent/US11345715B2/en active Active
-
2021
- 2021-03-17 JP JP2021043270A patent/JP2021105007A/ja active Pending
-
2022
- 2022-04-29 US US17/733,974 patent/US12378258B2/en active Active
-
2025
- 2025-06-30 US US19/255,790 patent/US20260062423A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI864472B (zh) | 抗體的特異性偶聯 | |
| US20230165930A1 (en) | Conjugate of a tubulysin analog with branched linkers | |
| JP7853711B2 (ja) | チューブリシン類縁体と細胞結合分子との共役体の製剤 | |
| CN113423430B (zh) | 含支链连接子的鹅膏毒素偶联物 | |
| ES2996807T3 (en) | Biologically active molecules, conjugates thereof, and therapeutic uses | |
| JP2025108449A (ja) | 細胞結合分子とカンプトテシン類縁体との共役体 | |
| JP2024023191A (ja) | 架橋ピロロベンゾジアゼピン二量体（ｐｂｄ）誘導体及びその共役体 | |
| ES2781523T3 (es) | Conjugados de moléculas de unión celular con agentes citotóxicos | |
| KR20220024914A (ko) | 분지형 링커를 사용한 세포독성제 대 세포 결합 분자의 접합체 | |
| EP3791897A1 (en) | Hsp90 inhibitor drug conjugates | |
| KR20170083998A (ko) | 유도형질로 활성화되는 다기능성 항암제 전구체, 이의 제조방법 및 이의 용도 | |
| KR20260014538A (ko) | 항체-약물 접합체에 의한 전립선암 및 다른 종양의 표적 치료 | |
| JP2016523825A (ja) | 腎毒性活性物質からの保護のための接合体 | |
| KR20210068060A (ko) | 주사용 조성물 | |
| TW202540145A (zh) | 胜肽及包含該胜肽之偶聯物 | |
| JP2015120657A (ja) | ペプチド及びヒト肝細胞選択的薬物送達複合体 | |
| CA3105541C (en) | Cross-linked pyrrolobenzodiazepine dimer (pbd) derivative and its conjugates | |
| EA053258B1 (ru) | Конъюгат аматоксинового аналога с разветвленными линкерами | |
| BR112021006160A2 (pt) | composto conjugado, célula tumoral, composição farmacêutica, e, agentes sinérgicos | |
| EA053191B1 (ru) | Конъюгат аналога тубулизина с разветвленными линкерами | |
| EA048944B1 (ru) | Сшитое производное димера пирролобензодиазепина (pbd) и его конъюгаты | |
| NZ710814B2 (en) | Biologically active molecules, conjugates thereof, and therapeutic uses |